xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05975879</url>
    </required_header>
    <id_info>
      <org_study_id>Artneo_2021</org_study_id>
      <nct_id>NCT05975879</nct_id>
    </id_info>
    <brief_title>A Study of the Feasibility of Using the Dietary Supplement &quot;ARTNEO&quot; in Patients With Osteoathritis</brief_title>
    <official_title>Multicenter, Prospective, Double-blind, Placebo-controlled, Randomized Study of the Feasibility of Using the Dietary Supplement &quot;ARTNEO®&quot;, Capsules for Oral Administration in Patients With Stage II-III Primary Knee Osteoarthritis</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>NPO Petrovax</agency>
        <agency_class>Industry</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>NPO Petrovax</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The goal of this clinical study is to evaluate the effectiveness of the properties that&#xD;
        support the functional state of the joints and the safety of the dietary supplement for food&#xD;
        ARTNEO®, oral capsules, in patients with stage II-III primary osteoarthritis of the knee&#xD;
        joint.&#xD;
  &#xD;
        The main questions it aims to answer are:&#xD;
  &#xD;
          1. To evaluate the effectiveness of the joint functional state-supporting properties of&#xD;
             dietary supplement ARTNEO®, capsules for oral administration, in patients with stage&#xD;
             II-III primary osteoarthritis of the knee joint;&#xD;
  &#xD;
          2. To evaluate the safety of dietary supplement ARTNEO®, capsules for oral administration,&#xD;
             in patients with stage II-III primary osteoarthritis of the knee joint.&#xD;
  &#xD;
        Participants will be randomly distributed equally among two groups:&#xD;
  &#xD;
          -  Group 1 &quot;ARTNEO&quot; (106 people): patients take the study dietary supplement ARTNEO®, 1&#xD;
             capsule 1 time per day for 6 months;&#xD;
  &#xD;
          -  Group 2 &quot;Placebo&quot; (106 people): patients take placebo 1 capsule 1 time per day for 6&#xD;
             months.&#xD;
      </textblock>
    </brief_summary>
    <overall_status>Completed</overall_status>
    <start_date type="Actual">May 31, 2022</start_date>
    <completion_date type="Actual">April 17, 2023</completion_date>
    <primary_completion_date type="Actual">February 28, 2023</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <primary_purpose>Supportive Care</primary_purpose>
      <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Change in WOMAC-T score</measure>
      <time_frame>Baseline to month 6</time_frame>
      <description>Change in total WOMAC score (WOMAC-T) at Visit 7 (Day 180 ± 4) from start of study dietary supplement/placebo compared to baseline (at Visit 2, Day 1).</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Change in the mean score on the subscales of WOMAC</measure>
      <time_frame>Baseline to months 1, 2, 3, 4, 6</time_frame>
      <description>Change in the mean score on the subscales of WOMAC (pain, stiffness, functional impairment) at Visit 3 (day 30 ± 2), Visit 4 (day 60 ± 2), Visit 5 (day 90 ± 3), Visit 6 (day 120 ± 3) ) and Visit 7 (Day 180 ± 4) compared to baseline (at Visit 2, Day 1);</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in WOMAC-T score (expt month 6)</measure>
      <time_frame>Baseline to months 1, 2, 3, 4</time_frame>
      <description>Change in total WOMAC score (WOMAC-T) at Visit 3 (day 30 ± 2), Visit 4 (day 60 ± 2), Visit 5 (day 90 ± 3), Visit 6 (day 120 ± 3) compared to basal value (on Visit 2, day 1)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in KOOS</measure>
      <time_frame>Baseline to months 1, 2, 3, 4, 6</time_frame>
      <description>Changes in target joint functional state assessment according to KOOS (Knee injury and Osteoarthritis Outcome Score) at Visit 3 (day 30 ± 2), Visit 4 (day 60 ± 2), Visit 5 (day 90 ± 3), Visit 6 (day 120 ± 3) and Visit 7 (day 180 ± 4) compared to baseline (at Visit 2, day 1);</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Ibuprofen intake</measure>
      <time_frame>Baseline to month 6</time_frame>
      <description>Cumulative oral dose of ibuprofen since day 1 (Visit 2, day 1) and number of patients (%) reporting ibuprofen use;</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Drop-out number</measure>
      <time_frame>Baseline to month 6</time_frame>
      <description>The number of patients dropping out (%) due to the need to prescribe non-steroidal anti-inflammatory drugs (NSAIDs) and other pain medications (with the exception of the drug &quot;rescue&quot; ibuprofen in the doses established by the protocol) or the need to increase the dose allowed under the protocol (more than 1200 mg / day) of ibuprofen;</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>EQ-5D assessment</measure>
      <time_frame>Baseline to month 6</time_frame>
      <description>Baseline EQ-5D Health Assessment (Visit 2, Day 1) at Visit 3 (Day 30 ± 2), Visit 4 (Day 60 ± 2), Visit 5 (Day 90 ± 3), Visit 6 ( day 120 ± 3) and Visit 7 (day 180 ± 4)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Pain VAS assessment</measure>
      <time_frame>Baseline to month 1, 2, 3, 4, 6</time_frame>
      <description>Pain assessment in the target knee on 100 mm visual analog scale (VAS) relative to baseline (Visit 2, Day 1) at Visit 3 (Day 30 ± 2), Visit 4 (Day 60 ± 2), Visit 5 (day 90 ± 3), Visit 6 (day 120 ± 3) and Visit 7 (day 180 ± 4)</description>
    </secondary_outcome>
    <other_outcome>
      <measure>Synovitis severity</measure>
      <time_frame>Baseline to month 6</time_frame>
      <description>Assessing the severity of synovitis according to the results of ultrasound examination of the target knee joint from the basal level (Visit 2, Day 1) at Visit 7 (Day 180 ± 4)</description>
    </other_outcome>
    <other_outcome>
      <measure>14-day pain VAS assessment</measure>
      <time_frame>Baseline to day 14</time_frame>
      <description>Assessment of the severity of pain when walking in the target knee joint on a 100-mm visual analog scale (VAS) relative to the basal level (Visit 2, day 1) on day 14±1.</description>
    </other_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Actual">212</enrollment>
    <condition>Osteoarthritis, Knee</condition>
    <condition>Osteoarthritis</condition>
    <condition>Knee Osteoarthritis</condition>
    <condition>Knee Arthritis</condition>
    <condition>Knee Discomfort</condition>
    <condition>Knee Pain Swelling</condition>
    <condition>Knee Pain Chronic</condition>
    <arm_group>
      <arm_group_label>ARTNEO</arm_group_label>
      <arm_group_type>Active Comparator</arm_group_type>
      <description>1 capsule 1 time per day for 6 months</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Placebo</arm_group_label>
      <arm_group_type>Placebo Comparator</arm_group_type>
      <description>1 capsule 1 time per day for 6 months</description>
    </arm_group>
    <intervention>
      <intervention_type>Dietary Supplement</intervention_type>
      <intervention_name>undenaturated collagen type II, methylsulfonylmethane, boswellia serrata, vitamin D3 (cholecalciferol), vitamin C (ARTNEO)</intervention_name>
      <description>Release form: capsules with an average weight of 585 mg. Active ingredients: MCM (methylsulfonylmethane) 300 mg, vitamin C (ascorbic acid) 80 mg, boswellia extract (65% boswellic acids) 50.05 mg, undenatured (native) type II collagen 40 mg, vitamin D3 (cholecalciferol) 400 IU.&#xD;
  Suggested Use: Adults, 1 capsule daily with meals.</description>
      <arm_group_label>ARTNEO</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Dietary Supplement</intervention_type>
      <intervention_name>Placebo</intervention_name>
      <description>Release form: capsules with an average weight of 585 mg. No active ingredients.</description>
      <arm_group_label>Placebo</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            1. Voluntarily signed informed consent to participate in the study;&#xD;
  &#xD;
            2. Men and women in postmenopause, aged 40-75 years, capable of independent movement, BMI&#xD;
               18-30 kg/m2;&#xD;
  &#xD;
            3. Verified primary gonarthrosis according to the American College of Rheumatology&#xD;
               criteria at least 6 months before enrollment in the study (in the presence of pain in&#xD;
               the knee joint and radiological signs of gonarthrosis in combination with one of the&#xD;
               following signs: crepitus in the joint or morning stiffness in the joint for less than&#xD;
               30 min);&#xD;
  &#xD;
            4. II-III radiological stage of gonarthrosis according to the Kellgren-Lawrence&#xD;
               classification with a predominant lesion of the medial tibiofemoral area of the knee&#xD;
               joint;&#xD;
  &#xD;
            5. Severity of pain in the assessed knee joint at the time of the screening visit from 40&#xD;
               or more on 100-mm VAS while walking;&#xD;
  &#xD;
            6. Ability to understand the rules of the study, willingness to follow them;&#xD;
  &#xD;
            7. Willingness to limit the diet (soy, avocado, passion fruit, pineapple, turmeric,&#xD;
               linseed, rapeseed, soybean oils, chia seeds, walnuts, decoction of willow bark, pine,&#xD;
               wormwood, L-carnitine, etc. should be excluded);&#xD;
  &#xD;
            8. Consent of the men during the study and within 30 days after its completion to use the&#xD;
               methods of contraception described in the protocol of this study.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            1. Individual intolerance to the active or excipients of the ARTNEO® dietary supplement&#xD;
               (undenatured type II collagen + methylsulfonylmethane + Boswellia serrata extract +&#xD;
               vitamin C + Vitamin D3), placebo and the &quot;rescue&quot; drug ibuprofen;&#xD;
  &#xD;
            2. Intolerance to eggs, poultry, shellfish;&#xD;
  &#xD;
            3. History of trauma or surgery on the target knee joint (other than diagnostic&#xD;
               arthroscopy more than 60 days old at study entry), expected surgery (within 6 months&#xD;
               following inclusion);&#xD;
  &#xD;
            4. Coronary artery bypass grafting in medical history;&#xD;
  &#xD;
            5. Diseases, the presence of which, from the point of view of the research physician,&#xD;
               puts the patient's health at risk in case of participation in the study or potentially&#xD;
               complicates the interpretation of the results of the study (may affect the assessment&#xD;
               of endpoints):&#xD;
  &#xD;
                 -  Known or suspected malignancy at the time of screening or in the previous 2&#xD;
                    years, other than completely healed skin cancer in situ;&#xD;
  &#xD;
                 -  History of gouty arthritis;&#xD;
  &#xD;
                 -  Malabsorption syndrome, celiac disease, short bowel syndrome, intestinal&#xD;
                    lymphangiectasia;&#xD;
  &#xD;
                 -  Peptic ulcer of the stomach and duodenum (in the acute phase or in the acute&#xD;
                    stage), gastrointestinal bleeding, Crohn's disease, ulcerative colitis at the&#xD;
                    time of screening or according to medical history for the last 4 months before&#xD;
                    the screening visit;&#xD;
  &#xD;
                 -  Hemophilia, hemorrhagic diathesis at the time of screening or according to&#xD;
                    medical history for the last 4 months before the screening visit, constant use of&#xD;
                    anticoagulants and antiplatelet agents according to the medical history for the&#xD;
                    last 4 months before the screening visit;&#xD;
  &#xD;
                 -  Ischemic heart disease, cerebrovascular disease in the acute stage or&#xD;
                    decompensation at the time of screening or according to medical history for the&#xD;
                    last 4 months before the screening visit;&#xD;
  &#xD;
                 -  Chronic obstructive pulmonary disease (COPD), bronchial asthma according to&#xD;
                    medical history;&#xD;
  &#xD;
                 -  Diagnosed moderate or severe chronic renal failure at the time of screening or&#xD;
                    based on medical history in the last 4 months prior to the screening visit;&#xD;
  &#xD;
                 -  Moderate to severe hepatic dysfunction as determined by history (any acute liver&#xD;
                    disease, toxic liver disease, cirrhosis, decompensated liver failure) at the time&#xD;
                    of screening or from medical history in the last 4 months prior to the screening&#xD;
                    visit;&#xD;
  &#xD;
                 -  The presence of rheumatological diseases according to the medical history;&#xD;
  &#xD;
            6. Mental and / or neurological diseases with partial or complete loss of legal capacity;&#xD;
  &#xD;
            7. Presence or suspicion of drug, alcohol or drug addiction;&#xD;
  &#xD;
            8. Intra-articular injection into the target knee joint:&#xD;
  &#xD;
                 -  Hyaluronates - less than 6 months prior to randomization;&#xD;
  &#xD;
                 -  Glucocorticosteroids less than 1 month prior to the randomization visit.&#xD;
  &#xD;
                 -  PRP therapy - less than 6 months prior to randomization&#xD;
  &#xD;
            9. The need for constant use of glucocorticoids in any dosage form;&#xD;
  &#xD;
           10. Use, including single use, of paracetamol, NSAIDs in any dosage form, and other pain&#xD;
               medications within the last 48 hours prior to the randomization visit. Use within 7&#xD;
               days before randomization of certain natural products (such as soy, avocado, passion&#xD;
               fruit, pineapple, turmeric, linseed, rapeseed, soybean oils, chia seeds, walnuts,&#xD;
               decoction of willow bark, pine, mugwort), L-carnitine;&#xD;
  &#xD;
           11. The use of glucosamine or chondroitin during the last 3 months before randomization&#xD;
               with a course duration of more than 3 months (if the duration of the course of&#xD;
               glucosamine or chondroitin was less than 3 months, then this therapy must be abandoned&#xD;
               throughout the study from the moment of the screening visit);&#xD;
  &#xD;
           12. Use of ω-3 polyunsaturated fatty acid preparations within 14 days prior to&#xD;
               randomization, therapeutic doses of fish oils (≥ 2 g/day) and shark cartilage&#xD;
               preparations within 6 months prior to randomization (except vitamin D3);&#xD;
  &#xD;
           13. Participation in any clinical trial currently or in the previous 30 days or 5&#xD;
               half-lives (whichever is longer) prior to the Screening visit;&#xD;
  &#xD;
           14. History of oral undenatured type II collagen therapy in the last 4 months prior to the&#xD;
               screening visit;&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>40 Years</minimum_age>
      <maximum_age>75 Years</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Ludmila Alekseeva, MD</last_name>
      <role>Principal Investigator</role>
      <affiliation>FSBSI &quot;Research Institute of Rheumatology named after V.A. Nasonova&quot;</affiliation>
    </overall_official>
    <location>
      <facility>
        <name>NIMK Vashe Zdorovie LLC</name>
        <address>
          <city>Kazan</city>
          <zip>420097</zip>
          <country>Russian Federation</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Federal State Budgetary Scientific Institution &quot;Research Institute of Rheumatology named after V.A. Nasonova&quot;</name>
        <address>
          <city>Moscow</city>
          <zip>115522</zip>
          <country>Russian Federation</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Pirogov Russian National Research Medical University</name>
        <address>
          <city>Moscow</city>
          <zip>117997</zip>
          <country>Russian Federation</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Research Center Eco-Safety LLC</name>
        <address>
          <city>Saint Petersburg</city>
          <zip>191119</zip>
          <country>Russian Federation</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Energiia Zdoroviya LLC</name>
        <address>
          <city>Saint Petersburg</city>
          <zip>194156</zip>
          <country>Russian Federation</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>&quot;Medical Sanitary Unit No. 157&quot; LLC</name>
        <address>
          <city>Saint Petersburg</city>
          <zip>196066</zip>
          <country>Russian Federation</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Research Center Eco-Safety LLC</name>
        <address>
          <city>Saint Petersburg</city>
          <zip>196143</zip>
          <country>Russian Federation</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Zvezdnaya Clinic LLC</name>
        <address>
          <city>Saint Petersburg</city>
          <zip>196158</zip>
          <country>Russian Federation</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Meili LLC</name>
        <address>
          <city>Saint Petersburg</city>
          <zip>199397</zip>
          <country>Russian Federation</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>State Health Institution &quot;Tula Regional Clinical Dermatovenerologic Dispensary&quot;</name>
        <address>
          <city>Tula</city>
          <zip>300053</zip>
          <country>Russian Federation</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Ulyanovsk Regional Clinical Hospital</name>
        <address>
          <city>Ulyanovsk</city>
          <zip>432017</zip>
          <country>Russian Federation</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Private educational institution of additional professional education 'Institute for advanced training and professional retraining of personnel</name>
        <address>
          <city>Yaroslavl</city>
          <country>Russian Federation</country>
        </address>
      </facility>
    </location>
    <location_countries>
      <country>Russian Federation</country>
    </location_countries>
    <verification_date>July 2023</verification_date>
    <study_first_submitted>July 27, 2023</study_first_submitted>
    <study_first_submitted_qc>August 3, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 4, 2023</study_first_posted>
    <last_update_submitted>August 3, 2023</last_update_submitted>
    <last_update_submitted_qc>August 3, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 4, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>undenatured type ii collagen</keyword>
    <keyword>collagen</keyword>
    <keyword>Boswellia serrata</keyword>
    <keyword>methylsulfonylmethane</keyword>
    <keyword>osteoarthritis</keyword>
    <keyword>knee pain</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Osteoarthritis</mesh_term>
      <mesh_term>Osteoarthritis, Knee</mesh_term>
    </condition_browse>
    <intervention_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Vitamin D</mesh_term>
      <mesh_term>Cholecalciferol</mesh_term>
      <mesh_term>Vitamins</mesh_term>
      <mesh_term>Dimethyl sulfone</mesh_term>
    </intervention_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05975879
  org study id: Artneo_2021
  nct id: NCT05975879
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  The goal of this clinical study is to evaluate the effectiveness of the properties that
        support the functional state of the joints and the safety of the dietary supplement for food
        ARTNEO®, oral capsules, in patients with stage II-III primary osteoarthritis of the knee
        joint.
  
        The main questions it aims to answer are:
  
          1. To evaluate the effectiveness of the joint functional state-supporting properties of
             dietary supplement ARTNEO®, capsules for oral administration, in patients with stage
             II-III primary osteoarthritis of the knee joint;
  
          2. To evaluate the safety of dietary supplement ARTNEO®, capsules for oral administration,
             in patients with stage II-III primary osteoarthritis of the knee joint.
  
        Participants will be randomly distributed equally among two groups:
  
          -  Group 1 "ARTNEO" (106 people): patients take the study dietary supplement ARTNEO®, 1
             capsule 1 time per day for 6 months;
  
          -  Group 2 "Placebo" (106 people): patients take placebo 1 capsule 1 time per day for 6
             months.
  allocation: Randomized
  intervention model: Parallel Assignment
  primary purpose: Supportive Care
  masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  measure: Change in WOMAC-T score
  time frame: Baseline to month 6
  description: Change in total WOMAC score (WOMAC-T) at Visit 7 (Day 180 ± 4) from start of study dietary supplement/placebo compared to baseline (at Visit 2, Day 1).
  measure: Change in the mean score on the subscales of WOMAC
  time frame: Baseline to months 1, 2, 3, 4, 6
  description: Change in the mean score on the subscales of WOMAC (pain, stiffness, functional impairment) at Visit 3 (day 30 ± 2), Visit 4 (day 60 ± 2), Visit 5 (day 90 ± 3), Visit 6 (day 120 ± 3) ) and Visit 7 (Day 180 ± 4) compared to baseline (at Visit 2, Day 1);
  measure: Change in WOMAC-T score (expt month 6)
  time frame: Baseline to months 1, 2, 3, 4
  description: Change in total WOMAC score (WOMAC-T) at Visit 3 (day 30 ± 2), Visit 4 (day 60 ± 2), Visit 5 (day 90 ± 3), Visit 6 (day 120 ± 3) compared to basal value (on Visit 2, day 1)
  measure: Change in KOOS
  time frame: Baseline to months 1, 2, 3, 4, 6
  description: Changes in target joint functional state assessment according to KOOS (Knee injury and Osteoarthritis Outcome Score) at Visit 3 (day 30 ± 2), Visit 4 (day 60 ± 2), Visit 5 (day 90 ± 3), Visit 6 (day 120 ± 3) and Visit 7 (day 180 ± 4) compared to baseline (at Visit 2, day 1);
  measure: Ibuprofen intake
  time frame: Baseline to month 6
  description: Cumulative oral dose of ibuprofen since day 1 (Visit 2, day 1) and number of patients (%) reporting ibuprofen use;
  measure: Drop-out number
  time frame: Baseline to month 6
  description: The number of patients dropping out (%) due to the need to prescribe non-steroidal anti-inflammatory drugs (NSAIDs) and other pain medications (with the exception of the drug "rescue" ibuprofen in the doses established by the protocol) or the need to increase the dose allowed under the protocol (more than 1200 mg / day) of ibuprofen;
  measure: EQ-5D assessment
  time frame: Baseline to month 6
  description: Baseline EQ-5D Health Assessment (Visit 2, Day 1) at Visit 3 (Day 30 ± 2), Visit 4 (Day 60 ± 2), Visit 5 (Day 90 ± 3), Visit 6 ( day 120 ± 3) and Visit 7 (day 180 ± 4)
  measure: Pain VAS assessment
  time frame: Baseline to month 1, 2, 3, 4, 6
  description: Pain assessment in the target knee on 100 mm visual analog scale (VAS) relative to baseline (Visit 2, Day 1) at Visit 3 (Day 30 ± 2), Visit 4 (Day 60 ± 2), Visit 5 (day 90 ± 3), Visit 6 (day 120 ± 3) and Visit 7 (day 180 ± 4)
  measure: Synovitis severity
  time frame: Baseline to month 6
  description: Assessing the severity of synovitis according to the results of ultrasound examination of the target knee joint from the basal level (Visit 2, Day 1) at Visit 7 (Day 180 ± 4)
  measure: 14-day pain VAS assessment
  time frame: Baseline to day 14
  description: Assessment of the severity of pain when walking in the target knee joint on a 100-mm visual analog scale (VAS) relative to the basal level (Visit 2, day 1) on day 14±1.
  arm group label: ARTNEO
  arm group type: Active Comparator
  description: 1 capsule 1 time per day for 6 months
  arm group label: Placebo
  arm group type: Placebo Comparator
  description: 1 capsule 1 time per day for 6 months
  intervention type: Dietary Supplement
  intervention name: undenaturated collagen type II, methylsulfonylmethane, boswellia serrata, vitamin D3 (cholecalciferol), vitamin C (ARTNEO)
  description: Release form: capsules with an average weight of 585 mg. Active ingredients: MCM (methylsulfonylmethane) 300 mg, vitamin C (ascorbic acid) 80 mg, boswellia extract (65% boswellic acids) 50.05 mg, undenatured (native) type II collagen 40 mg, vitamin D3 (cholecalciferol) 400 IU.
  Suggested Use: Adults, 1 capsule daily with meals.
  arm group label: ARTNEO
  intervention type: Dietary Supplement
  intervention name: Placebo
  description: Release form: capsules with an average weight of 585 mg. No active ingredients.
  arm group label: Placebo
  criteria: 
  gender: All
  minimum age: 40 Years
  maximum age: 75 Years
  healthy volunteers: No
  last name: Ludmila Alekseeva, MD
  role: Principal Investigator
  affiliation: FSBSI "Research Institute of Rheumatology named after V.A. Nasonova"
  facility: 
  facility: 
  facility: 
  facility: 
  facility: 
  facility: 
  facility: 
  facility: 
  facility: 
  facility: 
  facility: 
  facility: 
  country: Russian Federation
  responsible party type: Sponsor
  mesh term: Osteoarthritis
  mesh term: Osteoarthritis, Knee
  mesh term: Vitamin D
  mesh term: Cholecalciferol
  mesh term: Vitamins
  mesh term: Dimethyl sulfone
  sharing ipd: No